MDMB-BINACA (MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as ADB-BUTINACA and MDMB-5'Br-BUTINACA, and is believed to have similar effects.[1]
![]() | |
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C19H27N3O3 |
Molar mass | 345.443 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.